Abbott Laboratories is set to roll out its Volt PFA System in the U.S., following federal approval, and continue expanding ...
Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...
Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...
Zacks Investment Research on MSN
Abbott stock may benefit following Volt PFA's FDA approval
Abbott Laboratories ABT recently received FDA approval for its Volt PFA System to treat patients battling atrial fibrillation (AFib). The company is expected to begin commercial PFA cases in the ...
Medical Device Network on MSN
FDA approves Abbott’s Volt PFA system for atrial fibrillation
The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for patients with atrial fibrillation (AFib). The approval follows earlier CE ...
Abbott can now compete with Medtronic, Boston Scientific and J&J in the U.S. for the fast-growing pulsed field ablation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback